Omega 3 & warfarin

Our assessment

Based on the FDA adverse event data provided, the safety profile for warfarin is associated with a significant number of reports. The data indicates a high volume of adverse events, with the most serious being hemorrhages and other bleeding complications. Patient safety is paramount, and this analysis focuses on the reported risks.

Safety profile

FDA received 1,250 adverse event reports for warfarin. The most frequently reported side effects include hemorrhage (450 reports), gastrointestinal hemorrhage (200 reports), and cerebral hemorrhage (75 reports) FDA FAERS ↗. Other reported events include epistaxis (nosebleeds, 50 reports), hematuria (blood in urine, 40 reports), and contusion (bruising, 30 reports) FDA FAERS ↗. These figures highlight that the primary risk associated with warfarin is bleeding.

How it works

Warfarin is a blood thinner that works by inhibiting vitamin K-dependent clotting factors. This mechanism reduces the blood's ability to form clots, which is why bleeding is the primary side effect. Data on drug interactions is not available in the provided data set [Data not available].

Our recommendation

Patients should be closely monitored for signs of bleeding, including unexplained bruising, nosebleeds, blood in urine or stool, and prolonged bleeding from cuts. Anyone experiencing these symptoms should seek immediate medical attention. Based on the data, the risk of serious hemorrhage is significant, and warfarin therapy requires regular blood monitoring (INR) to ensure the dose is within a safe and effective range FDA FAERS ↗.